• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

用于治疗感染的载抗菌剂接枝共聚物纳米颗粒

Antimicrobial Loaded Graft-Copolymer Nanoparticles for Treatment of Infections.

作者信息

Soler Yadiel Varela, Xu William, Lima Mariana R N, McDonald Jessica, Jagpal Sugeet K, Kirn Thomas J, Hussain Sabiha, Devore David I, Roth Charles M

机构信息

Department of Chemical and Biochemical Engineering, Rutgers University, Piscataway, NJ 08854, United States.

Department of Biomedical Engineering, Rutgers University, Piscataway, NJ 08854, United States.

出版信息

bioRxiv. 2025 Jul 4:2025.07.03.663093. doi: 10.1101/2025.07.03.663093.

DOI:10.1101/2025.07.03.663093
PMID:40631083
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12236493/
Abstract

Nearly 80% of cystic fibrosis patients are affected by persistent lung infections, with being one of the major culprits. Treatment of is further complicated by its ability to form biofilms. Anionic compounds within the biofilm and thick cystic fibrosis mucus interact with cationic antimicrobials, hindering treatment efficacy. In this study, we investigated the treatment of lung infections by delivering antimicrobials via polyelectrolyte surfactants that are composed of an anionic poly(alkylacrylic acid) backbone with grafted polyetheramine pendent chains. When combined with cationic antimicrobials, they selfassemble into nanoparticles via electrostatic interactions. We assessed the role of backbone chemistry and graft density on nanoparticle physical properties and evaluated the antimicrobial activity of these formulations against planktonic and biofilm cultures of strains derived from clinical isolates. All synthesized polyelectrolyte surfactants demonstrated high levels of antimicrobial encapsulation, with the extent of drug bound corresponding to the calculated hydrophilic-lipophilic balance values. We observed significantly increased antimicrobial activity against planktonic cultures using nanoformulations containing one of the polyelectrolyte surfactants, PMAA-g-10%J. In contrast, all tested nanoformulations retained, but did not increase, activity against biofilms. By monitoring membrane potentials and nanoparticle uptake, it was found that the nanoparticles directly associate with the bacterial cell membranes, which may enhance drug delivery and underlie the improved activity against the planktonic bacteria. In conclusion, we provide a proof of concept for the design of polyelectrolyte surfactants for the nanoencapsulation and delivery of cationic drug cargoes against infections.

摘要

近80%的囊性纤维化患者受到持续性肺部感染的影响,其中[病原体名称未给出]是主要病因之一。[病原体名称未给出]形成生物膜的能力使治疗进一步复杂化。生物膜内的阴离子化合物和浓稠的囊性纤维化黏液与阳离子抗菌剂相互作用,阻碍了治疗效果。在本研究中,我们研究了通过由带有接枝聚醚胺侧链的阴离子聚(烷基丙烯酸)主链组成的聚电解质表面活性剂递送抗菌剂来治疗肺部感染。当与阳离子抗菌剂结合时,它们通过静电相互作用自组装成纳米颗粒。我们评估了主链化学和接枝密度对纳米颗粒物理性质的作用,并评估了这些制剂对源自临床分离株的[病原体名称未给出]菌株的浮游菌和生物膜培养物的抗菌活性。所有合成的聚电解质表面活性剂都表现出高水平的抗菌剂包封,药物结合程度与计算出的亲水亲油平衡值相对应。我们观察到,使用含有聚电解质表面活性剂之一PMAA-g-10%J的纳米制剂对浮游菌培养物的抗菌活性显著增加。相比之下,所有测试的纳米制剂对生物膜的活性保持不变,但没有增加。通过监测膜电位和纳米颗粒摄取,发现纳米颗粒直接与细菌细胞膜结合,这可能增强药物递送并成为对浮游细菌活性改善的基础。总之,我们为设计用于阳离子药物货物纳米封装和递送以对抗[病原体名称未给出]感染的聚电解质表面活性剂提供了概念验证。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/b2e2f2f67169/nihpp-2025.07.03.663093v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/fd8d604b64f8/nihpp-2025.07.03.663093v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/c80082e2b302/nihpp-2025.07.03.663093v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/1a79a90769fd/nihpp-2025.07.03.663093v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/d1292ad1fb54/nihpp-2025.07.03.663093v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/b2e2f2f67169/nihpp-2025.07.03.663093v1-f0005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/fd8d604b64f8/nihpp-2025.07.03.663093v1-f0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/c80082e2b302/nihpp-2025.07.03.663093v1-f0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/1a79a90769fd/nihpp-2025.07.03.663093v1-f0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/d1292ad1fb54/nihpp-2025.07.03.663093v1-f0004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1aac/12236493/b2e2f2f67169/nihpp-2025.07.03.663093v1-f0005.jpg

相似文献

1
Antimicrobial Loaded Graft-Copolymer Nanoparticles for Treatment of Infections.用于治疗感染的载抗菌剂接枝共聚物纳米颗粒
bioRxiv. 2025 Jul 4:2025.07.03.663093. doi: 10.1101/2025.07.03.663093.
2
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.支气管镜引导下的囊性纤维化抗菌治疗。
Cochrane Database Syst Rev. 2024 May 3;5(5):CD009530. doi: 10.1002/14651858.CD009530.pub5.
3
Antibiotic treatment for non-tuberculous mycobacteria lung infection in people with cystic fibrosis.囊性纤维化患者非结核分枝杆菌肺部感染的抗生素治疗
Cochrane Database Syst Rev. 2025 Mar 27;3(3):CD016039. doi: 10.1002/14651858.CD016039.
4
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.支气管镜引导下的囊性纤维化抗菌治疗
Cochrane Database Syst Rev. 2013 Dec 23(12):CD009530. doi: 10.1002/14651858.CD009530.pub2.
5
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.支气管镜引导下的囊性纤维化抗菌治疗
Cochrane Database Syst Rev. 2018 Sep 17;9(9):CD009530. doi: 10.1002/14651858.CD009530.pub4.
6
Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.支气管镜引导下的囊性纤维化抗菌治疗
Cochrane Database Syst Rev. 2016 Jan 21(1):CD009530. doi: 10.1002/14651858.CD009530.pub3.
7
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.标准抗菌药敏试验与生物膜抗菌药敏试验用于指导囊性纤维化患者的抗生素治疗
Cochrane Database Syst Rev. 2017 Oct 5;10(10):CD009528. doi: 10.1002/14651858.CD009528.pub4.
8
Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis.标准抗菌药敏试验与生物膜抗菌药敏试验在指导囊性纤维化抗生素治疗中的应用
Cochrane Database Syst Rev. 2015 Mar 5(3):CD009528. doi: 10.1002/14651858.CD009528.pub3.
9
Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.根除囊性纤维化患者体内铜绿假单胞菌的抗生素策略。
Cochrane Database Syst Rev. 2017 Apr 25;4(4):CD004197. doi: 10.1002/14651858.CD004197.pub5.
10
Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.针对囊性纤维化患者中耐甲氧西林金黄色葡萄球菌(MRSA)的清除干预措施。
Cochrane Database Syst Rev. 2022 Dec 13;12(12):CD009650. doi: 10.1002/14651858.CD009650.pub5.

本文引用的文献

1
Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives.肺部给药的纳米制剂:过去、现在与未来展望
Pharmaceutics. 2024 Jan 24;16(2):161. doi: 10.3390/pharmaceutics16020161.
2
Cystic Fibrosis: A Review.囊性纤维化:综述。
JAMA. 2023 Jun 6;329(21):1859-1871. doi: 10.1001/jama.2023.8120.
3
Respiratory Infection and Inflammation in Cystic Fibrosis: A Dynamic Interplay among the Host, Microbes, and Environment for the Ages.囊性纤维化中的呼吸感染和炎症:宿主、微生物和环境之间的动态相互作用贯穿始终。
Int J Mol Sci. 2023 Feb 17;24(4):4052. doi: 10.3390/ijms24044052.
4
The biofilm life cycle: expanding the conceptual model of biofilm formation.生物膜的生命周期:扩展生物膜形成的概念模型。
Nat Rev Microbiol. 2022 Oct;20(10):608-620. doi: 10.1038/s41579-022-00767-0. Epub 2022 Aug 3.
5
Tolerance and resistance of microbial biofilms.微生物生物膜的耐受性和抗药性。
Nat Rev Microbiol. 2022 Oct;20(10):621-635. doi: 10.1038/s41579-022-00682-4. Epub 2022 Feb 3.
6
Hybrid Lipid/Polymer Nanoparticles to Tackle the Cystic Fibrosis Mucus Barrier in siRNA Delivery to the Lungs: Does PEGylation Make the Difference?用于解决肺部 siRNA 递送至囊性纤维化粘液屏障的杂交脂质/聚合物纳米颗粒:PEG 化是否有区别?
ACS Appl Mater Interfaces. 2022 Feb 16;14(6):7565-7578. doi: 10.1021/acsami.1c14975. Epub 2022 Feb 2.
7
Nebulizer systems: a new frontier for therapeutics and targeted delivery.雾化器系统:治疗学和靶向递药的新前沿。
Ther Deliv. 2022 Jan;13(1):31-49. doi: 10.4155/tde-2021-0070. Epub 2021 Nov 12.
8
Elucidating the mechanism by which synthetic helper peptides sensitize Pseudomonas aeruginosa to multiple antibiotics.阐明合成辅助肽使铜绿假单胞菌对多种抗生素敏感的机制。
PLoS Pathog. 2021 Sep 3;17(9):e1009909. doi: 10.1371/journal.ppat.1009909. eCollection 2021 Sep.
9
Polymyxins, the last-resort antibiotics: Mode of action, resistance emergence, and potential solutions.多黏菌素类抗生素:作用模式、耐药性产生及潜在解决方案。
J Biosci. 2021;46(3). doi: 10.1007/s12038-021-00209-8.
10
The Mechanistic Action of Biosynthesised Silver Nanoparticles and Its Application in Aquaculture and Livestock Industries.生物合成银纳米颗粒的作用机制及其在水产养殖和畜牧业中的应用。
Animals (Basel). 2021 Jul 14;11(7):2097. doi: 10.3390/ani11072097.